Dietary Supplement
L-carnosine
L-carnosine is a dietary supplement with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DIETARY SUPPLEMENT
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
1
25%
Ph not_applicable
2
50%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
Nucleophilic Defense Against PM Toxicity (NEAT Trial)
NCT03314987
completedphase_2
Carnosine and Cognitive Training in Schizophrenia
NCT02686697
completedphase_1
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
NCT02808624
completednot_applicable
L-Carnosine for Bipolar I Disorder
NCT00177463
Clinical Trials (4)
Showing 4 of 4 trials
NCT03314987Not Applicable
Nucleophilic Defense Against PM Toxicity (NEAT Trial)
NCT02686697Phase 2
Carnosine and Cognitive Training in Schizophrenia
NCT02808624Phase 1
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
NCT00177463Not Applicable
L-Carnosine for Bipolar I Disorder
All 4 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 4